Dashboard - Summary
Market Stats Last updated: 14 December 2018 - 7:29pm
|52 Week Low||A$28.38|
|52 Week High||A$39.38|
|Historic Value (Latest Results)||A$36.22 (+16.2%)|
|Future Value (Forecast FY)||A$35.56 (+14.1%)|
|Forecast Return on Equity||12.5%|
|Current Dividend Yield||3.9%|
|Forecast Dividend Yield||4.1%|
|Forecast Dividend Franking||100.0%|
5 Year Growth Rate
|Dividend Per Share||-24.7%|
|Earnings Per Share||-19.7%|
|Equity Per Share||-0.8%|
Woodside Petroleum is the largest producer of oil and gas in Australia. WPL along with its subsidiaries is engaged in hydrocarbon exploration, evaluation, development, production and marketing.
WPL has been operating its Australian project, the North West Shelf (NWS), for 28 years. NWS remains one of the world’s premier liquefied natural gas (LNG) facilities.
Following the successful start-up of the Pluto LNG plant in 2012, WPL now operates six of the seven LNG processing trains in Australia.
WPL also operates four oil floating production storage and offloading (FPSO) vessels in the Exmouth Basin, North West Shelf and Timor Sea. WPL is committed to expanding its LNG portfolio through premium developments including the Browse Floating LNG (FLNG) Development, which is in the design stage.
WPL’s international assets include deep-water production facilities in the Gulf of Mexico plus acreage in the USA, Brazil, Peru, Republic of Korea and the Canary Islands.
For the six months ended 30 June 2018, Woodside Petroleum Limited revenues increased 27% to $2.39B. Net income increased 6% to $541M. Revenues reflect Pluto Business unit segment increase of 29% to $1.34B. Net income was partially offset by Exploration and Development Costs-Austra increase from $55M to $176M, Write-offs ofExploration and evaluation increase from $5M to $87M (expense).
Research - Analyst Research
Key Financials - Profit & Loss
The following financial information reflects selected key items from the profit and loss statement and is not intend to be a full representation of the accounts. All data is provided by Thomson Reuters and displayed where available. During reporting season some line items may be incomplete for up to 30 days after the reporting date.
Key Financials - Balance Sheet
The following financial information reflects selected key items from the balance sheet and is not intend to be a full representation of the accounts. All data is provided by Thomson Reuters and displayed where available. During reporting season some line items may be incomplete for up to 30 days after the reporting date.
Key Financials - Cash Flow
The following financial information reflects selected key items from the cash flow statement and is not intend to be a full representation of the accounts. All data is provided by Thomson Reuters and displayed where available. During reporting season some line items may be incomplete for up to 30 days after the reporting date.
Key Financials - Financial Summary
We've broken the financial statements into the three areas we commonly look at when evaluating the performance and valuation of a stock. The key aim is for us to ascertain whether the company is growing its equity base through profitability. This can provide a lens as to whether the business is well run or whether it is reliant on new capital or debt raisings to fund growth.
All data provided by Thomson Reuters and updated daily where relevant.
Key Ratios - Profitability
A key factor in our analysis of a company's long term value generation. We focus on a company's ability to generate profits based the amount of equity invested by shareholders. All base data is provided by Thomson Reuters.
Key Ratios - Dividends
Our dividend calcuations are based on dividends a company has actually paid out relative to its share price at the end of the most recent financial year. Our calculation may therefore differ from other websites. All base data for our calculations is provided by Thomson Reuters.
Key Ratios - Financial Strength
Pay special attention to our financial health measure. Over the longer term, companies with a stronger financial health are more likely to survive and sustain their business in economic downturns and flourish in the recovery.
Valuation - Analyst Updates
View a full record of stocks as they have entered and been released from analyst review.
|Date||Market Price||Historic Value
|Future Value Y1
Valuation - Valuation History
View a full historic record of our valuations and underlying assumptions. Where valuations were changed multiple times within 7 days, while under analyst review, to only the final valuation is recorded.
|Date of Review||Forecast Return on Equity||Distributed||Reinvested||Required Return||Exchange Rate||Valuation|
Valuation - Adjust Valuation
Valuation - Future Value
View our forecast valuation inputs and financial forcecast data for up to the next 3 financial years.
All historic and forecast financial data is provided by Thomson Reuters and displayed where available. Forecast values are based on consensus estimates any may be edited by our Analysts upon reviewing the stock.
Valuation - Valuations and Performance
|Historic Value (Latest Result):||A$36.22||Future Value (Forecast Financial Year)||A$35.56||Required Return:||9.5%|
Historic and Future Performance
View the historically achieved performance metrics for the company and the forecast performance metrics based on consensus estimates. See how our adopted performance metrics compare.
We endeavour to maintain the accuracy of data provided on this website, by using information prepared from a wide variety of sources, which StocksInValue, to the best of its knowledge and belief, considers accurate. However, StocksInValue makes no representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability or availability of the information provided.